Novavax, Inc. (NASDAQ: NVAX), which is also considered one of the frontrunners in the coronavirus vaccine, announced a few additions to its executive team.What Happened: The company said Wednesday it has appointed AstraZeneca plc (NYSE: AZN) veteran Filip Dubovsky as SVP and Chief Medical Officer, overseeing its medical and clinical affairs and related activities.Dubovsky has more than 20 years of experience in infectious diseases and was overseeing clinical development of early and late-stage infectious disease and vaccine assets at AstraZeneca's biologics arm MedImmune.The company also announced the appointment of Silvia Taylor, as SVP, Investor Relations and Corporate Affairs.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Why It Matters: Novavax reported in late March positive Phase 3 results for its influenza vaccine candidate NanoFlu.In late May, the company commenced human studies of its SARS-CoV-2 vaccine candidate, NVX-CoV2373. It also...
In this article you are going to find out whether hedge funds think Fastly, Inc. (NYSE:FSLY) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among […]...
